Vertex Pharmaceuticals (VRTX) Capital Leases (2011 - 2025)

Vertex Pharmaceuticals has reported Capital Leases for 15 years, with the latest figure at $111.4 million in Q1 2025.

• On a quarterly basis, Capital Leases fell 69.18% year-over-year to $111.4 million in Q1 2025; TTM through Mar 2025 was $111.4 million, a 69.18% decrease from a year earlier, with the FY2024 full-year figure at $112.8 million, down 70.01% from the prior year.
• Capital Leases was $111.4 million for Q1 2025 at Vertex Pharmaceuticals, down from $112.8 million in the prior quarter.
• The five-year high for Capital Leases was $530.3 million in Q1 2021, with the low at $111.4 million in Q1 2025.
• Average Capital Leases over 5 years is $386.1 million, with a median of $417.6 million recorded in 2023.
• The sharpest annual moves came in 2021 and 2024: Capital Leases increased 0.55% in 2021, then plunged 70.79% in 2024.
• Over 5 years, Capital Leases stood at $509.8 million in 2021, then retreated by 15.5% to $430.8 million in 2022, then slipped by 12.7% to $376.1 million in 2023, then slumped by 70.01% to $112.8 million in 2024, then dropped by 1.24% to $111.4 million in 2025.
• The last three Capital Leases figures came in at $111.4 million (Q1 2025), $112.8 million (Q4 2024), and $114.0 million (Q3 2024), per Business Quant data.